Medical tech firm STRATA's Q3 revenue misses estimates as demand in international markets softens

STRATA Skin Sciences

13/11/2025 21:19

Overview

STRATA Q3 2025 revenue fell 21% yr/yr, missing analyst expectations

Net loss for Q3 2025 reduced to $1.6 mln from $2.1 mln yr/yr

Company's recurring revenue increased 3% yr/yr, equipment revenue fell 60%

Outlook

STRATA anticipates revenue growth from expanded CPT codes for reimbursement

STRATA plans to manage costs and expand patient pool through DTC efforts

Result Drivers

CPT CODE EXPANSION - Progress in expanding CPT codes for reimbursement expected to triple covered patient population in US

LITIGATION OUTCOME - Positive developments in lawsuit against LaserOptek, adding new defendants, improving chances for collecting damages

INTERNATIONAL MARKET SOFTNESS - Revenue decline attributed to instability in international trade policy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$6.90 mln
$8.23 mln (2 Analysts)
Q3 Net Income
-$1.60 mln
Q3 Gross Profit
$4.20 mln
Q3 Recurring Revenue
$5.50 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Strata Skin Sciences Inc is $8.00, about 79% above its November 12 closing price of $1.68

Press Release: ID:nGNX5RnWMr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)